Clinically, immune checkpoint blockade with anti-PD-1/PD-L1 agents such as nivolumab and pembrolizumab frequently induces lichenoid eruptions, including lichen planus and lichen planus pemphigoides, as a form of immune-related adverse event. The gene discussed is CD274; the disease is lichen planus.